Compare AstraZeneca plc (AZN) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Verizon Communications Inc — how do they compare? AstraZeneca plc trades at $168.72 (market cap $253.13B), while Verizon Communications Inc trades at $43.11 (market cap $177.34B). The key difference: AstraZeneca plc is the larger of the two by market cap, and Verizon Communications Inc pays the higher dividend (6.66%). Which is the better fit depends on your goals.
| AZN | VZ | |
|---|---|---|
Market Cap | $253.13B | $177.34B |
Sector | Health | Media |
52-Week High | $209.48 | $51.38 |
52-Week Low | $137.44 | $38.40 |
Enterprise Value | $279.37B | $364.84B |
Dividend Yield | 1.92% | 6.66% |
Volume | — | 22,584,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Verizon (VZ) trades at $42.68, up 1.33% today, with a bearish technical signal from moving averages but recent earnings beats. The stock offers a 6.7% dividend yield with a consensus price target of $47.57, indicating 11.5% upside. Revenue grew to $138.19B in 2025, with a net income margin of 12.46%, while debt levels remain elevated at $144B total debt. Recent news highlights competitive threats from SpaceX's Starlink but also new partnerships like the 5G deal with BMW.
Outlook: VZ presents a value opportunity with a low P/E of 10.4 and strong cash flow, but faces significant competitive and debt-related risks. The stock is suitable for income-focused investors seeking defensive yield, though growth is constrained by industry saturation and rising capital expenditures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
